It was only nine months ago that Idorsia announced a CEO change, tapping Srishti Gupt | Idorsia is gearing up for another CEO ...

Eli Lilly scored $408 million in U.S. sales of eczema treatment Ebglyss in its first full year on the market in 2025. | With ...

BioMarin will discontinue dosing and enrollment of its phase 2 trials for Voxzogo—currently approved in achondroplasia, a ...

With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population ...

A federal judge in Boston blocked significant parts of the HHS' vaccination agenda and effectively stopped an upcoming vaccines advisory panel from meeting later this week as originally scheduled.

The White House’s direct-to-consumer (DTC) platform, TrumpRx, is steadily expanding its catalogue, with products from GSK and Amgen the latest to join the collection of drugs offered through the pr | ...

Johnson & Johnson is suing a former oncology medical affairs employee, alleging a massive and “malicious” stealing of trade secrets.  | Johnson & Johnson is suing a former oncology medical affairs ...

From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. | From its ...

Veeva is paying approximately $100 million to acquire Ostro, according to this week’s announcement, comprising a combination ...

Twelve months ago, drugmakers came roaring into 2025, fueled by a massive year of growth that peaked in the fourth quarter of ...

Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. | Eli Lilly—which has already staged multiple efforts in ...

Simtra BioPharma Solutions was issued a warning letter by the FDA after an inspection uncovered a number of problems at the ...